Patent details

EP2922876 Title: IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

Basic Information

Publication number:
EP2922876
PCT Application Number:
US2013071077
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP138563572
PCT Publication Number:
WO2014081872
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
French Title of Invention:
PRODUITS PHARMACEUTIQUES PEPTIDIQUES AMÉLIORÉS POUR LA RÉSISTANCE À L'INSULINE
German Title of Invention:
VERBESSERTE PEPTIDARZNEIMITTEL FÜR INSULINRESISTENZ
SPC Number:

Dates

Filing date:
20/11/2013
Grant date:
10/10/2018
EP Publication Date:
30/09/2015
PCT Publication Date:
30/05/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
10/10/2018
EP B1 Publication Date:
10/10/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
20/11/2018
Expiration date:
20/11/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
03/10/2018
 
 

Name:
Mederis Diabetes, LLC
Address:
7515 Guinevere Drive, Sugar Land, Texas 77479, United States (US)

Inventor

Name:
NESTOR, John, J.
Address:
United States (US)

Priority

Priority Number:
201261728649 P
Priority Date:
20/11/2012
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/16; A61P 3/10; C07K 19/00;

Publication

European Patent Bulletin

1

Issue number:
201841
Publication date:
10/10/2018
Description:
Grant (B1)

2

Issue number:
201842
Publication date:
17/10/2018
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/03/2019 Outgoing Correspondence 1